Top 5 Infectious Disease Stories Week of March 2

News
Article

This week, the FDA-approved antiretroviral lenacapavir as it showed treatment benefits; Oral Vancomycin Prophylaxis was explored for preventing C difficile in stem cell transplant recipients; Research into the after-effects of SARS-CoV-2 (PASC) uncovers biomarkers for post-infection sequelae; Chronic hepatitis B worsens COVID-19 outcomes, and cabotegravir ultra-long-acting (CABULA) has shown positive results.

Related Videos
Related Content
A Multi-Year Analysis on Antimicrobial Use on Clostridioides difficile Infection

A Multi-Year Analysis on Antimicrobial Use on Clostridioides difficile Infection

April 18th 2024
Article
C difficile, Antimicrobials, and the Patients Most Affected

C difficile, Antimicrobials, and the Patients Most Affected

November 23rd 2022
Podcast
CDC Strategies Tested for Preventing Hospital-Onset C difficile

CDC Strategies Tested for Preventing Hospital-Onset C difficile

April 14th 2024
Article
C Diff Advocacy Organization Announces its National Summit Agenda

C Diff Advocacy Organization Announces its National Summit Agenda

April 11th 2024
Article
Community Acquired Pneumonia Often Inappropriately Diagnosed in Hospital Admissions

Community Acquired Pneumonia Often Inappropriately Diagnosed in Hospital Admissions

April 2nd 2024
Article
Effectiveness of Clostridioides Difficile (CDI) Infection Prevention Strategies in Acute Care

Effectiveness of Clostridioides Difficile (CDI) Infection Prevention Strategies in Acute Care

April 1st 2024
Article
© 2024 MJH Life Sciences

All rights reserved.